Insmed stock: Zacks highlights Brinsupri growth and FDA review

Published on 11/13/2026 at 22:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insmed stock remains tied to rapid Brinsupri uptake and a potential Arikayce label expansion. The FDA set a January 2027 decision date.

Commercial growth and regulatory outlook

Brinsupri revenue reached 400.1 million US dollars in the third quarter, while Arikayce revenue rose to 124.4 million US dollars.
Insmed raised its 2026 revenue ranges for Brinsupri and Arikayce after third-quarter revenue reached 524.4 million US dollars.
The FDA set January 28, 2027, as the target decision date for a potential Arikayce label expansion.

INSM, US4576693075, Illustration mit AI erstellt.

In an analyst blog published on November 11, Zacks highlighted Insmed's commercial momentum, led by Brinsupri and Arikayce. The company is combining faster product sales with regulatory opportunities for its respiratory portfolio.

Brinsupri revenue reached 400.1 million US dollars in the third quarter, up from 309.2 million US dollars in the second quarter. Arikayce revenue rose from 116.3 million US dollars to 124.4 million US dollars over the same period. Total third-quarter revenue reached 524.4 million US dollars, 268 percent above the prior-year quarter.

Higher guidance and regulatory catalyst

Insmed raised its 2026 Brinsupri revenue range to 1.35 billion to 1.40 billion US dollars, from 1.25 billion to 1.40 billion US dollars. The company also lifted its Arikayce range to 460 million to 470 million US dollars, from 450 million to 470 million US dollars.

The FDA granted Priority Review to Insmed's supplemental application seeking broader use of Arikayce beyond refractory Mycobacterium avium complex lung disease. The proposed expansion could include patients with newly diagnosed or recurrent infections. The agency set January 28, 2027, as the target decision date.

Insmed stock traded at 109.98 euros on Lang & Schwarz at 22:30 CET on Friday, November 13, 2026.